Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Clinical Gastroenterology and Hepatology, Elsevier BV, Vol. 11, No. 7 ( 2013-07), p. 808-814
    Type of Medium: Online Resource
    ISSN: 1542-3565
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2013
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 4257-4257
    Abstract: Abstract 4257 Iron in the plasma is bound to transferrin. The total iron binding capacity (TIBC) represents the maximum amount of iron that can be bound and is directly related to transferrin concentration. TIBC and serum transferrin concentration are increased in iron deficiency and decreased in iron overload. Recently, an association was reported between single nucleotide polymorphisms (SNPs) in the transferrin gene, TF, on chromosome 3q22.1, and serum transferrin levels (Benyamin et al. Am J Hum Genet. 2009;84:60-65). In the current study, we investigated whether the association between SNP rs3811647 in TF and transferrin levels (assessed by measurement of TIBC) is attributable to an effect on regulation of body iron status. The Personalized Medicine Research Project (PMRP) is the largest population-based biobank in the US containing genetic, phenotypic and environmental information on approximately 20,000 people. PMRP is part of the NHGRI-funded eMERGE (www.gwas.net) network. Previously, genotyping was performed on selected PMRP samples with the Illumina Human660W-Quad BeadChip platform. Eligible participants in the current study were 491 white men age ≥ 25 y and 747 white women ≥ 50 y with serum ferritin (SF) values collected between 1985 and 2010. Exclusion criteria included a diagnosis of celiac disease and previous phlebotomy treatment for hemochromatosis. Using TIBC as a marker of serum transferrin for eligible participants having multiple measurements, mean TIBC and median serum ferritin were considered in analyses. Subsets of participants included cases of iron deficiency with multiple measurements of SF ≤ 12 μg/L and iron-replete controls (all measurements of SF 〉 100 μg/L in men, all SF 〉 50 μg/L in women). Regression analysis was used to examine the association between outcomes (case-control status, natural log of serum ferritin, TIBC) and each of 54 SNPs, adjusted for gender. These SNPS included three in iron genes (rs3811647 in TF, rs1800562 in HFE, and rs2302591 in FLVCR2) and were selected for analysis on the basis of a GWAS of iron-related measures conducted in a separate study of iron deficient cases and iron-replete controls identified in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Statistical significance was defined as a SNP showing a p-value for association less than 0.001; the threshold is based on a nominal alpha of 0.05 with Bonferroni multiple test correction for the total number of SNPs analyzed. Genotypes were coded as 0, 1, or 2, indicating the number of copies of the less frequent of the two alleles in the genotype. Values for mean TIBC were analyzed for 1175 individuals (726 women, 449 men); median SF was analyzed for 1143 participants (693 women, 450 men). In the subset analyses, there were 258 cases with iron deficiency and 505 controls. The strongest statistical evidence for association with TIBC was found for SNP rs3811647 in the TF gene (observed p-value = 6.05 × 10-6, adjusted for gender). The minor allele frequency for SNP rs3811647 was 0.34. The regression slope parameter was 14.5, indicating that increasing copies of the minor allele were associated with increasing levels of TIBC. In contrast, there was no significant association with SF (observed p=0.22) or case vs. control status (odds ratio 1.26, observed p=0.21), adjusted for gender. For the C282Y mutation in the HFE gene, increasing copies of the minor allele were associated with decreasing levels of TIBC (observed p-value = 0.002, adjusted for gender). The fact that SNP rs3811647 in the TF gene was associated with TIBC levels but showed no significant association with either serum ferritin or the presence of iron deficiency does not support a role for the SNP in regulation of body iron status. Thus, the SNP may affect TIBC independently of iron status. Elevation of transferrin levels could help withhold iron from microorganisms, conferring protection from infection. Use of TIBC as an index of iron deficiency may be confounded by the existence in the population of the minor allele in the rs3811647 genotype, resulting in elevation of TIBC without a corresponding decrease in body storage iron. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Cell Reports, Elsevier BV, Vol. 18, No. 10 ( 2017-03), p. 2331-2342
    Type of Medium: Online Resource
    ISSN: 2211-1247
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 2649101-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: PLoS ONE, Public Library of Science (PLoS), Vol. 6, No. 3 ( 2011-3-31), p. e17390-
    Type of Medium: Online Resource
    ISSN: 1932-6203
    Language: English
    Publisher: Public Library of Science (PLoS)
    Publication Date: 2011
    detail.hit.zdb_id: 2267670-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 4048-4048
    Abstract: Abstract 4048 Poster Board III-983 Introduction Iron deficiency is the most common nutritional disorder in the world with an estimated two billion affected persons. Although commonly considered environmental in origin, the existence of multiple genetic disorders of iron metabolism in man, rodents and other vertebrates suggest a genetic contribution to iron deficiency. Methods: The Hemochromatosis and Iron Overload Screening (HEIRS) Study is a multi-center, multi-ethnic study in which transferrin saturation (TS), serum ferritin (SF), and HFE mutations were determined in 101,168 adults. To identify genomic locations associated with iron deficiency, we performed a genome-wide association study (GWAS) using DNA collected from white HEIRS Study participants who had SF ≤ 12 μg/L (cases) and an equal number of white controls (SF 〉 100 μg/L in men, SF 〉 50 μg/L in women) frequency-matched to cases by sex and geographic location. Men aged ≥ 25 y and women ≥ 50 y were included in both groups. Tissue body iron, an index of iron deficiency, was estimated from serum transferrin receptor (sTfR) and SF. Genotyping was performed with the Illumina HumanCNV370K Beadchip platform. Quality control filters excluded single nucleotide polymorphisms (SNPs) or samples with 〉 5% missing genotypes, SNPs showing heterozygosity or Hardy-Weinberg deviations (P 〈 10−7), and SNPs with minor allele frequency 〈 0.02. Population admixture/structure was assessed using principal component analysis. Regression analysis was used to examine the association between outcomes (case-control status, tissue body iron, serum ferritin, transferrin receptor, serum iron, total iron-binding capacity [TIBC], and unsaturated iron-binding capacity [UIBC] ) and each SNP genotype variable; covariates included age, sex, and geographic location. Replication for 56 SNPs was conducted in a population attending primary care clinics at a Veterans Affairs (VA) medical center using the iPlex platform. Eligibility within the VA replication population was restricted to age and self-reported white ethnicity as for the HEIRS subset from a total of 2559 people (138 women). VA participants with SF ≤ 20 μg/L were classified as iron-deficient cases and frequency matched 1:2 with controls (men with SF 〉 100 μg/L and women with SF 〉 50 μg/L). Results The GWAS genomic control parameter was not significantly different from 1.0. There were 392 cases (96 men) and 390 controls (96 men) in the HEIRS subset GWAS with average age (SD) of 59 (10) y and 61 (11) y, respectively. Geometric mean SF (minimum, maximum), and mean (SD) for sTfR and tissue body iron in the HEIRS subset were 7.5 (1.2, 12) μg/L, 6.4 (3.77) mg/kg and -2.0 (2.50) for cases and 141 (51, 881) μg/L, 3.0 (0.98) mg/kg and 10.8 (2.5) for controls. After quality control tests, GWAS analysis included genotype data for 331,060 SNPs in 734 individuals (364 cases, 370 controls). For the VA replication population there were 67 male and 11 female cases, and 136 male and 27 female controls for whom DNA was successfully prepared; the average age (SD) was 68 (12) y for cases and 65 (11) y for controls. Regression analysis identified seven SNPs within four independent regions that replicated associations found in the GWAS (GWAS P 〈 1×10-4 and VA P 〈 0.05).The SNP rs6735681 on chromosome 2p24 was associated with serum iron (GWAS P 〈 3.9×10-5, VA P=0.038). Three SNPs on chromosome 2p14 (rs6750096, rs2698541 and rs2698530) significantly influenced both TIBC and UIBC (GWAS P 〈 2.9×10-5, VA P 〈 0.04 for all). Two SNPs in the TF gene region on chromosome 3q22 also showed significant effects on TIBC and UIBC (GWAS P 〈 4.7×10-6, VA P 〈 0.03 for all). The SNP rs10512064 on chromosome 9q21 was associated with serum ferritin concentration and tissue body iron (GWAS P 〈 2.5×10-5, VA P 〈 0.05 for both). Conclusion: From these GWAS and replication studies, we have identified three new genetic loci and one known iron gene, TF, associated with iron phenotype variability. These results point to specific loci as targets for gene identification and TF polymorphisms as determinants of iron metabolism, which in turn may play a role in regulation of body iron status. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 22, No. 1_Supplement ( 2016-01-01), p. PR06-PR06
    Abstract: Whole genome sequencing has rapidly emerged as the preferred method for unbiased genomic interrogation. Leveraging this technology, we have developed a precision medicine clinical research protocol for pediatric, adolescent, and young adult cancer patients. The primary objective of this study is to arrive at genome informed treatment recommendations for individual patients suffering from aggressive and/or worsening disease in a clinically relevant time frame. The second objective is to survey the genomic landscape of newly diagnosed and recurrent/refractory patients. To accomplish this, we have employed an interdisciplinary workflow including a customized bioinformatic analysis pipeline, contextual biological interpretation of the data, and case reviews during weekly molecular tumor board meetings. Here we report the results of having sequenced over 50 patients diagnosed with both common and rare malignancies. Factors affecting the successful identification of therapeutically actionable targets and subsequent intervention are varied. The most consistent findings are the increased mutation burden in patients who have received chemotherapy and/or radiation prior to tissue collection. Lastly, we highlight the realistic opportunities, challenges, and insight gained from an ongoing single institution experience. This abstract is also presented as Poster 27. Citation Format: Troy A. McEachron, Keri B. Zabokrtsky, Aaron F. Sassoon, Sara Nasser, Tyler Izatt, Chad P. Garner, David W. Craig, John D. Carpten, Leonard S. Sender. Precision medicine for newly diagnosed and refractory/recurrent pediatric cancer patients: Lessons learned from “N=1” studies. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; Jun 13-16, 2015; Salt Lake City, UT. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(1_Suppl):Abstract nr PR06.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: The Prostate, Wiley, Vol. 64, No. 2 ( 2005-07-01), p. 168-174
    Type of Medium: Online Resource
    ISSN: 0270-4137 , 1097-0045
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2005
    detail.hit.zdb_id: 1494709-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 20_Supplement ( 2014-10-15), p. A34-A34
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 20_Supplement ( 2014-10-15), p. A34-A34
    Abstract: Despite advancements made in pediatric and adolescent oncology over the last 60 years, there is still a subset of patients for whom front-line therapy has proven ineffective in curing their cancer. Roughly 20 percent of pediatric and adolescent patients with cancer will experience recurrent or refractory disease and successful outcomes diminish with each subsequent failed therapy. In an effort to improve outcomes in these critical patients, the Genomic Research Program was established in the Hyundai Cancer Institute at Children's Hospital of Orange County (CHOC). The primary goals of this research program are to collect high-quality tumor and germline specimens from patients with recurrent or refractory cancer, to perform whole genome sequencing on both tumor and germline samples and mRNA sequencing on the tumor sample to obtain and characterize the molecular signature of the cancer, and to better understand how the disease circumvented therapy and to identify ways in which it may be more effectively treated. To date (July 2013), 99 participants have been identified for study; 72 of whom had suspect recurrent or refractory disease and 27 of whom had a suspect new cancer diagnosis. All but two patients were recruited at CHOC. Of those identified, 76 participants and/or families provided consent. The most common reason for not pursuing consent was administrative; potential patients were not scheduled for a standard-of-care procedure during which research specimen(s) could be obtained or the potential patient was identified too close to the scheduled procedure to complete the consent process. When patients declined consent, the most common reason given was the skin punch biopsy(ies) needed from those with leukemia. Whole genome sequencing of the tumor and normal genomes has been undertaken for 32 patients, 25 of which have also had mRNA sequencing of their tumor. Of the patients with genome sequencing completed, seven cases are brain tumors, seven cases are leukemias, five cases are sarcomas, two cases are lymphomas and the remaining cases include one each of hemophagocytic lymphohistiocytosis (HLH), melanoma, myelodysplastic syndrome (MDS), neuroblastoma, and Wilms tumor. We have developed and optimized a process for identifying and delivering personalized treatment. The process begins with patient consent, followed by tumor and germline tissue procurement, DNA and RNA extraction, and shipment of the specimens to one of our sequencing providers. Data is received from the sequencing service and analyzed in two independent bioinformatics pipelines in order to maximize the validity of the results. Genomic variation, identified by whole genome sequencing, is integrated with gene expression information from mRNA sequencing, to develop a molecular profile of each tumor. The process culminates with a molecular profile tumor board meeting where results are interpreted, prioritized, and a clinical action plan (if appropriate) is developed for the individual patient. The amount of time required to go from consent to tumor board can be currently as little as three weeks, although process time is highly correlated with cost. The development of this clinical sequencing process is now focused on scalability and on increased throughput. Our experience to date has demonstrated the feasibility and effectiveness of clinical sequencing in pediatric and adolescent oncology. Citation Format: Keri B. Zabokrtsky, Chad P. Garner, Troy McEachron, Nicole Mosher, Ali G. Darwish, Leonard S. Sender. Creation of a personalized, molecular-based approach to the treatment of recurrent or refractory pediatric and adolescent cancers. [abstract]. In: Proceedings of the AACR Special Conference on Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes; Nov 3-6, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;74(20 Suppl):Abstract nr A34.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Society of Hematology ; 2003
    In:  Blood Vol. 102, No. 13 ( 2003-12-15), p. 4563-4566
    In: Blood, American Society of Hematology, Vol. 102, No. 13 ( 2003-12-15), p. 4563-4566
    Abstract: The goal of this study was to determine whether statistical modeling of population data for a phenotypic marker could reflect a major locus gene defect. Identifying mutations in the HFE gene makes it possible to assess the association between transferrin saturation (TS) subpopulations and HFE mutations. Data were analyzed from 27 895 white patients who attended a health appraisal clinic and who had TS and common mutations of HFE determined. Mixture distribution modeling of TS was performed, and the proportion of HFE mutations in TS subpopulations was assessed on a probability basis. Three subpopulations of TS were identified, consistent with Hardy-Weinberg conditions for major locus effects. For men, 72% of the subpopulation with the highest mean TS had HFE gene mutations; they were primarily homozygotes or compound heterozygotes. Seventy-three percent of the subpopulation with moderate mean TS also had HFE gene mutations; they were predominantly simple heterozygotes. Sixty-seven percent of the subpopulation with the lowest mean TS were wild-type homozygotes. Similar results were observed for women. These results suggest that statistical modeling of population clinical laboratory test data can reveal the influence of a major locus gene defect and perhaps can be applied to other aspects of body metabolism than iron. (Blood. 2003;102:4563-4566)
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2003
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 118, No. 21 ( 2011-11-18), p. 2105-2105
    Abstract: Abstract 2105 The existence of multiple inherited disorders of iron metabolism in man, rodents and other vertebrates suggests genetic contributions to iron deficiency. We hypothesized that common variants in genes involved in iron metabolism may modulate susceptibility or resistance to the development of iron deficiency in humans. To examine the association between single nucleotide polymorphisms (SNPs) in key genes involved in iron metabolism pathways, we previously performed a genome-wide association study using DNA collected from white men aged ≥25 y and women ≥50 y in the Hemochromatosis and Iron Overload Screening (HEIRS) Study with serum ferritin (SF) ≤12 μg/L (cases) and controls (SF 〉 100 μg/L in men, SF 〉 50 μg/L in women). We now report on a multiethnic follow-up association study of HEIRS participants. Candidate SNPs were identified from our GWAS and the scientific literature. Population samples of whites, African Americans, Hispanics, and Asians from the U.S. and Canada were analyzed separately for association between SNPs and case-control status and each of seven quantitative outcomes including serum iron, total iron-binding capacity (TIBC), unsaturated iron-binding capacity (UIBC), transferrin saturation, SF, serum transferrin receptor, and body iron. There were 1084 white (357 cases, 727 controls), 153 Asian (51 cases, 102 controls), 221 African American (77 cases, 144 controls) and 233 of 239 Hispanic individuals (79 cases, 160 controls) that passed quality control. For the African-American and Hispanic samples, ancestry proportions were estimated based on genotypes of ancestry informative markers. Regression analysis was used to examine the association between case-control status and quantitative serum iron measures and 1134, 1115, 1113 and 1134 SNP genotypes in the white, African-American, Hispanic, and Asian population samples, respectively. Model predictors included age, sex, the estimated ancestry proportion (for African American and Hispanic only), genotype, and measured covariates that showed nominally significant associations with the outcome. Three chromosomal regions showed evidence of association across multiple populations, including SNPs in the TF gene on chromosome 3q22, the TMPRSS6 gene on chromosome 22q12, and loci on chromosome 18q21. SNP rs1421312 in TMPRSS6 was associated with serum iron in whites (p=4.7×10−7) and was replicated in African Americans (p=0.0012).Twenty SNPs in the TF gene region were significantly associated with TIBC in the white sample (p 〈 4.4×10−5); six SNPs were replicated in other ethnicities (p 〈 0.01). SNP rs10904850 in the CUBN gene on 10p13 was significantly associated with serum iron in the African-American sample (P=1.0×10−5). Mutations in the TMPRSS6 gene have been implicated in iron-refractory iron deficiency anemia through linkage studies. We found a novel SNP in TMPRSS6 that was associated with serum iron in whites and replicated in African Americans, suggesting a role for this SNP in increasing the risk of iron deficiency in affected persons. Our results confirm known associations with iron measures and give evidence of their role in different ethnic groups, a unique aspect of this study, suggesting origins in a common founder. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages